DeutschNewstral
Article
Mmarketwatch.com on 2022-04-29 18:21
Lilly's experimental weight-loss drug may be a 'multibillion-dollar opportunity'4 min read
Related news
- MNIH to test Lilly's experimental monoclonal antibody treatment in mild and moderate COVID-19 casesmarketwatch.com
- MLilly's ambitious new drug Mounjaro fails to impress in the fourth quarter3 min readmarketwatch.com
- BFDA's Call on Lilly's Covid Drug Is Lifting a Partner's Beaten-Down Stock3 min readbarrons.com
- BAfter Lilly's Selloff, Citi Declares the Stock a Buy2 min readbarrons.com
- BThe FDA Rejected Lilly's Alzheimer's Drug. Why It's Only a Setback,3 min readbarrons.com
- MWhy the FDA didn't grant an approval to Lilly's Alzheimer's drug3 min readmarketwatch.com
- MLilly's new diabetes drug doubled sales expectations. It may also be used to treat obesity3 min readmarketwatch.com
AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill—As Weight Loss Drug Market GrowsForbes- Pfizer Pulls Experimental Twice-Daily Weight Loss Drug—Shares Slide 6% To Multiyear LowForbes
- BModerna Unveils Experimental Two-in-One Vaccine for Covid and the Flu2 min readbarrons.com
- MLilly's COVID-19 treatment receives emergency-use approval from FDA, stock jumps 3%marketwatch.com
Lilly's Dim Sum still shinesnwaonline.com
Drugmaker Lilly's forecast misses expectationsThe Salt Lake Tribune- MLilly's drug aimed at preventing Alzheimer's fails1 min readmarketwatch.com
- MLilly's stock falls on failed Alzheimer's studymarketwatch.com
Eli Lilly's experimental drug lowers risk of heart disease by 94%: studyNew York Post- Feds reject Lilly's rheumatoid arthritis pillThe Salt Lake Tribune
- ALilly's rheumatoid arthritis pill rejected by regulatorsapnewsarchive.com
Lilly's time to blossom, says CowanShropshire Star